galectin-3, CAS No.rp174094

Features and benefits
    Item Number
    rp174094
    Grouped product items
    SKUSizeAvailabilityPrice Qty
    rp174094-500μg
    500μg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $1,334.90
    rp174094-1mg
    1mg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $2,334.90

    Basic Description

    Product Namegalectin-3, CAS No.rp174094
    GradeMoligand™
    Specifications & PurityMoligand™

    Associated Targets(Human)

    LGALS3 Tchem Galectin-3 (0 Activities)
    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

    Product Specifications

    CASrp174094

    Certificates

    Certificate of Analysis(COA)

    Enter Lot Number to search for COA:

    Genetic information

    Reference
    • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
    • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
    • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
    • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
    • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
    • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
    • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
    • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
    • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
    • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more

    Related Documents

    References

    1. Henderson NC, Sethi T.  (2009)  The regulation of inflammation by galectin-3..  Immunol Rev,  230  (1): (160-71).  [PMID:19594635] [10.1021/op500134e]
    2. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ.  (2009)  Galectin-3: a novel mediator of heart failure development and progression..  Eur J Heart Fail,  11  (9): (811-7).  [PMID:19648160] [10.1021/op500134e]
    3. Streetly MJ, Maharaj L, Joel S, Schey SA, Gribben JG, Cotter FE.  (2010)  GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death..  Blood,  115  (19): (3939-48).  [PMID:20190189] [10.1021/op500134e]
    4. Delaine T, Collins P, MacKinnon A, Sharma G, Stegmayr J, Rajput VK, Mandal S, Cumpstey I, Larumbe A, Salameh BA et al..  (2016)  Galectin-3-Binding Glycomimetics that Strongly Reduce Bleomycin-Induced Lung Fibrosis and Modulate Intracellular Glycan Recognition..  Chembiochem,  17  (18): (1759-70).  [PMID:27356186] [10.1021/op500134e]
    5. Harazono Y, Kho DH, Balan V, Nakajima K, Zhang T, Hogan V, Raz A.  (2014)  Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cells..  Oncotarget,  (20): (9992-10001).  [PMID:25393982] [10.1021/op500134e]
    6. DeRoo EP, Wrobleski SK, Shea EM, Al-Khalil RK, Hawley AE, Henke PK, Myers DD Jr, Wakefield TW, Diaz JA.  (2015)  The role of galectin-3 and galectin-3-binding protein in venous thrombosis..  Blood,  125  (11): (1813-21).  [PMID:25428218] [10.1021/op500134e]
    7. Nakajima K, Kho DH, Yanagawa T, Harazono Y, Hogan V, Chen W, Ali-Fehmi R, Mehra R, Raz A.  (2016)  Galectin-3 Cleavage Alters Bone Remodeling: Different Outcomes in Breast and Prostate Cancer Skeletal Metastasis..  Cancer Res,  76  (6): (1391-402).  [PMID:26837763] [10.1021/op500134e]
    8. Sumida Y, Yoneda M.  (2018)  Current and future pharmacological therapies for NAFLD/NASH..  J Gastroenterol,  53  (3): (362-376).  [PMID:29247356] [10.1021/op500134e]
    9. Chan YC, Lin HY, Tu Z, Kuo YH, Hsu SD, Lin CH.  (2018)  Dissecting the Structure-Activity Relationship of Galectin-Ligand Interactions..  Int J Mol Sci,  19  (2): (1755-70).  [PMID:29382172] [10.3390/ijms19020392]

    Solution Calculators